Recurrent Breast Cancer Completed Phase 2 Trials for Erlotinib (DB00530)

Also known as: Breast Cancer Recurrent / Breast cancer NOS recurrent / Carcinoma breast recurrent / Breast carcinoma recurrent / Breast carcinoma NOS recurrent

IndicationStatusPhase
DBCOND0028640 (Recurrent Breast Cancer)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00733408Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast CancerTreatment